© 2019 IPHARMA

  • Facebook Social Icon
  • LinkedIn Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon


On June 22, 2016, IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct the Phase III clinical study of the medicinal product Levopront® (levodropropizine).

Protocol № LDP0114 "Multicenter open-label randomized clin...

Please reload

Please reload

Поиск по тегам